Challenges in the development of antimalarial drugs with causal prophylactic activity-Reference-Cited by-同舟云学术

Challenges in the development of antimalarial drugs with causal prophylactic activity

Published:1998-11 Issue:6 Volume:92 Page:577-579
ISSN:0035-9203
Container-title:Transactions of the Royal Society of Tropical Medicine and Hygiene
language:en
Short-container-title:Transactions of the Royal Society of Tropical Medicine and Hygiene

Author:

Chulay Jeffrey D.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Medicine,Parasitology

Link

http://academic.oup.com/trstmh/article-pdf/92/6/577/5426050/92-6-577.pdf

Reference25 articles.

1. Effect of pyrimethamine upon sporogony and pre-erythrocytic schizonts of Laverania falciparum;Bray;Bulletin of the World Health Organization,1959

2. The haemolytic effect of various regimens of primaquine with chloroquine in American negroes with G6PD deficiency and the lack of an effect of various antimalarial suppressive agents on erythrocyte metabolism;Brewer;Bulletin of the World Health Organization,1967

3. Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial;Brueckner;Antimicrobial Agents and Chemotherapy,1998

4. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial;Brueckner;American Journal of Tropical Medicine and Hygiene,1998

5. Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria;Chiodini;Journal of Antimicrobial Chemotherapy,1995

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. On the potential for discontinuing atovaquone-proguanil (AP) ad-hoc post-exposure and other abbreviated AP-regimens: Pharmacology, pharmacokinetics and perspectives;Travel Medicine and Infectious Disease;2023-03

2. Discontinuing atovaquone/proguanil prophylaxis ad-hoc post-exposure and during-travel dose-sparing prophylactic regimens against P. falciparum malaria: An update with pointers for future research;Travel Medicine and Infectious Disease;2022-09

3. Causal Prophylactic Efficacy of Primaquine, Tafenoquine, and Atovaquone-Proguanil AgainstPlasmodium cynomolgiin a Rhesus Monkey Model;Journal of Parasitology;2014-10

4. Identification and Validation of Tetracyclic Benzothiazepines as Plasmodium falciparum Cytochrome bc1 Inhibitors;Chemistry & Biology;2011-12

5. An alkaline comet assay study on the antimalarial drug atovaquone in human peripheral blood lymphocytes: a study based on clinically relevant concentrations;Journal of Applied Toxicology;2011-07-07